Back to top
more

Sage Therapeutics (SAGE)

(Delayed Data from NSDQ)

$8.41 USD

8.41
524,997

+0.22 (2.69%)

Updated Aug 23, 2024 03:59 PM ET

After-Market: $8.40 -0.01 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Factors Setting the Tone for Bristol-Myers (BMY) Q1 Earnings

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports first-quarter 2020 results.

Cronos (CRON) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Cronos (CRON) reports Q1 results.

Will Soliris & Ultomiris Drive Alexion's (ALXN) Q1 Earnings?

by Zacks Equity Research

Investors will focus on the performance of Soliris and Ultomiris along with other pipeline updates, when Alexion (ALXN) reports first-quarter 2020 results.

Incyte (INCY) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports first-quarter 2020 results.

Will Eylea & Dupixent Drive Regeneron's (REGN) Q1 Earnings?

by Zacks Equity Research

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports first-quarter 2020 results.

The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics

Nalak Das headshot

Buy 5 Top Health Care Stocks Ahead of Q1 Earnings Results

by Nalak Das

Economic activities came almost to a standstill in March. However, one sector that witnessed heightening activities is health care.

Sage Therapeutics' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Sage Therapeutics.

How Sage Therapeutics (SAGE) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Sage Therapeutics (SAGE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Sage Therapeutics (SAGE) in Focus: Stock Moves 9.3% Higher

by Zacks Equity Research

Sage Therapeutics (SAGE) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Why Sage Therapeutics (SAGE) Stock Might be a Great Pick

by Zacks Equity Research

Sage Therapeutics (SAGE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Proteostasis (PTI) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

We expect Proteostasis Therapeutics (PTI) to provide updates on its pipeline when its releases fourth-quarter 2019 results.

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

by Zacks Equity Research

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the fourth quarter driven by clinical studies on its lead pipeline candidate, Zygel.

Why Earnings Season Could Be Great for Sage Therapeutics (SAGE)

by Zacks Equity Research

Sage Therapeutics (SAGE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

NuCana (NCNA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

We expect NuCana (NCNA) to provide updates on its pipeline when it releases fourth-quarter results.

Actinium (ATNM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Actinium (ATNM) reports fourth-quarter 2019 results.

Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fourth-quarter 2019 results.

Assertio (ASRT) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

During Q4 earnings call, Assertio (ASRT) is likely to provide an update on its recently implemented cost-saving initiatives and the sales performance of its marketed drugs.

AcelRx (ACRX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

During Q4 investors' call, AcelRx (ACRX) is likely to provide an update on the sales uptake of its recently-unveiled product Dsuvia, which is approved for acute pain management.

Coherus (CHRS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

We expect Coherus BioSciences (CHRS) to provide updates on its pipeline when it releases fourth-quarter 2019 results.

Intellia (NTLA) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Intellia (NTLA) is likely to provide an update on the IND application for its lead candidate NTLA-2001, currently being developed to address transthyretin amyloidosis.

Guardant Health (GH) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

During Guardant Health's (GH) Q4 earnings call, investors' focus will be on the updates related to Guardant360 test and the colorectal cancer screening rates of its LUNAR-2 blood test.

Cyclacel (CYCC) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

We expect Cyclacel (CYCC) to provide updates on its pipeline when it releases fourth-quarter 2019 results.

Epizyme (EPZM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

We expect Epizyme (EPZM) to provide commercialization updates on its sarcoma drug when it releases fourth-quarter 2019 earnings.

What's in Store for Aimmune (AIMT) This Earnings Season?

by Zacks Equity Research

Aimmune (AIMT) is likely to provide an update on Palforzia's launch plans during Q4 investors' call. The drug gets an approval in January 2020 for the treatment of peanut allergy.